A lawsuit was filed on behalf of investors in Alcobra Ltd (NASDAQ:ADHD) shares over alleged securities laws violations and NASDAQ:ADHD investors should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 02/21/2017 -- The Shareholders Foundation announces that an investor, who purchased shares of Alcobra Ltd (NASDAQ:ADHD), filed a lawsuit in New York over alleged Securities Laws violations by Alcobra Ltd.
Investors who purchased shares of Alcobra Ltd (NASDAQ:ADHD) have certain options and for certain investors are short and strict deadlines running. Deadline: April 18, 2017. NASDAQ:ADHD investors should contact the Shareholders Foundation at email@example.com or call 858-779-1554.
The plaintiff claims that between August 13, 2015 and January 17, 2016 the defendants caused the Company to issue materially misleading statements and/or omit material information concerning the Company's second Phase III study for MDX in adults with attention deficit hyperactivity disorder ("ADHD"), the "MDX Evaluation in Adults – Study of Response and Efficacy," or the "MEASURE" study.
On January 17, 2017, Alcobra Ltd reported the top-line results from MEASURE, its second Phase 3 clinical trial for the investigational product Metadoxine Extended Release (MDX) for the treatment of ADHD in adult patients. Alcobra Ltd said that in this trial, MDX did not meet the primary endpoint of demonstrating a statistically significant difference from placebo in the change from baseline of the investigator rating of the Conners' Adult ADHD Rating Scales (CAARS).
Shares of Alcobra Ltd (NASDAQ:ADHD) declined on January 17, 2017, to as low as $0.83 per share.
On February 17, 2017, NASDAQ:ADHD shares closed at $1.25 per share.
Those who purchased shares of Alcobra Ltd have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego